Biotech · Public company · New York, NY, US
MiNK Therapeutics, Inc.
Ticker INKT · SEC CIK 0001840229
Track this companyFree. Adds MiNK Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials52 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline5
- agenT-797Phase 2 · PneumoniaClinicalTrials.gov · fetched Nov 12, 2026
- agenT-797Phase 1 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- agenT-797Phase 1 · Respiratory Distress Syndrome, AdultClinicalTrials.gov · fetched Nov 12, 2026
- agenT-797Phase 1 · Tumor, SolidClinicalTrials.gov · fetched Nov 12, 2026
- Approved ICIsPhase 1 · Tumor, SolidClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- BLinatumomab and iNKT in Relapsed B-Cell ALLPHASE1 · NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07869368 · fetched Nov 12, 2026
- A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory FailurePHASE2 · RECRUITING · started May 26, 2026ClinicalTrials.gov NCT07615010 · fetched Nov 12, 2026
- A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid TumorsPHASE1 · COMPLETED · started Jan 28, 2022ClinicalTrials.gov NCT05108623 · fetched Nov 12, 2026
- agenT-797 in Participants With Relapsed/Refractory Multiple MyelomaPHASE1 · COMPLETED · started Mar 29, 2021ClinicalTrials.gov NCT04754100 · fetched Nov 12, 2026
- A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDSPHASE1 · COMPLETED · started Sep 21, 2020ClinicalTrials.gov NCT04582201 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 23, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 15, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 19, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 8, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 14, 2025 · fetched Nov 12, 2026
NIH awards2
- Developing allogeneic iNKT cell adoptive therapy to improve outcomes for HSCT indicationsFiscal year 2026 · $306.5KNIH RePORTER 5R41AI192061-02 · fetched Nov 12, 2026
- Developing allogeneic iNKT cell adoptive therapy to improve outcomes for HSCT indicationsFiscal year 2025 · $306.5KNIH RePORTER 1R41AI192061-01 · fetched Nov 12, 2026